GlassScriptPhysician profile
Joanna Tolin
NPI 1366768996
$381.12
in general payments reported to CMS, 2019-2025
9 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2021: $69.62 · 2022: $27.78 · 2023: $37.60 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $170.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $113.96 | 2025 | Ozempic |
| Dexcom, INC. | $105.67 | 2019-2023 | Dexcom G6 Transmitter |
| Amgen INC. | $69.45 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $18.95 | 2025 | Yorvipath |
| Recordati_rare_diseases_inc. | $15.99 | 2023 | Isturisa, Signifor Lar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.98 | 2021 | |
| Shire North American Group INC | $15.42 | 2019 | |
| Medtronic Minimed, INC. | $13.73 | 2019 | |
| Zealand Pharma US, INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanna Tolin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.